drugset / Trial / NCT03108729

A Pediatric Drug Study to Determine the Long-term Safety and Tolerability in Children and Adolescents (4-17 Years in Age) Taking the Drug

NCT03108729

Phase 3 Withdrawn Sumitomo Pharma America, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A pediatric drug study to determine the long-term safety and tolerability in children and adolescents (4-17 years in age) taking the drug (elsicarbazepine acetate)

Timeline

Start
2017-07-06
Primary completion
2017-10-26
Completion
2017-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 300 mg
Subject Eslicarbazepine acetate Unknown 1600 mg

Indications